M
Michael Gottschalk
Researcher at University of California, San Diego
Publications - 43
Citations - 2611
Michael Gottschalk is an academic researcher from University of California, San Diego. The author has contributed to research in topics: Randomized controlled trial & Placebo. The author has an hindex of 23, co-authored 38 publications receiving 2378 citations. Previous affiliations of Michael Gottschalk include Boston Children's Hospital & Loyola University Chicago.
Papers
More filters
Journal ArticleDOI
The PedsQL™ in Type 1 and Type 2 Diabetes: Reliability and validity of the Pediatric Quality of Life Inventory™ Generic Core Scales and Type 1 Diabetes Module
James W. Varni,Tasha M. Burwinkle,Jenifer R. Jacobs,Michael Gottschalk,Francine R. Kaufman,Kenneth L. Jones +5 more
TL;DR: The results demonstrate the reliability and validity of the PedsQL in diabetes and may be used as an outcome measure for diabetes clinical trials and research.
Journal ArticleDOI
A disease-associated cellular immune response in type 1 diabetics to an immunodominant epitope of insulin
David G. Alleva,Paul D. Crowe,Liping Jin,William W. Kwok,Nicholas Ling,Michael Gottschalk,Paul J. Conlon,Peter A. Gottlieb,Amy L. Putnam,Amitabh Gaur +9 more
TL;DR: This study is the first demonstration of a cellular response to the (B9-23) insulin epitope in human type 1 diabetes and suggests that the mouse and human diseases have strikingly similar autoantigenic targets, a feature that should facilitate development of antigen-based therapeutics.
Journal ArticleDOI
Preparing Adolescents With Chronic Disease for Transition to Adult Care: A Technology Program
Jeannie S. Huang,Laura Terrones,Trevor Tompane,Lindsay Dillon,Mark Pian,Michael Gottschalk,Gregory J. Norman,L. Kay Bartholomew +7 more
TL;DR: Outcomes in ACD improved significantly among recipients of a generic, technology-based intervention, and a generic approach offers a cost-effective means of positively influencing transition outcomes.
Journal ArticleDOI
Metformin extended release treatment of adolescent obesity: a 48-week randomized, double-blind, placebo-controlled trial with 48-week follow-up
Darrell M. Wilson,Stephanie H. Abrams,Tandy Aye,Phillip D.K. Lee,Carine M. Lenders,Robert H. Lustig,Stavroula V. Osganian,Henry A. Feldman,Patricia Y. Fechner,Thomas N. Robinson,Bruce A. Buckingham,Trudy Esrey,Keniki McNeil,Beatrice Sorensen,Kirsten Wilson,Jeanne Davis,William J. Klish,Stephanie H. Abrams,Pam Holt,Cynthia Edwards,Linda Howard,Stephen E. Gitelman,Marcia S. Wertz,Jessica Breland,Tania Lihatsh,Anna Haddal,Pinchas Cohen,Sally Shupien,Janet Mooney,Elena Khanukhova,Helene Cohen,George A. Taylor,Christopher Duggan,Sam Nurko,Carol Sweeney,Katie Zhang,Maggie McCarthy,Michael Wake,Rajna Filip-Dhima,Charles G. Prober,Karen Urbanek,Alisa Kim,Anita Kelley,Christine Crabtree,Dennis M. Styne,Michael Gottschalk,Daniel E. Hale,Heidi Krause-Steinrauf +47 more
TL;DR: Metformin XR caused a small but statistically significant decrease in BMI when added to a lifestyle intervention program, as compared with placebo.
Journal ArticleDOI
Glimepiride versus metformin as monotherapy in pediatric patients with type 2 diabetes: a randomized, single-blind comparative study
TL;DR: Glimepiride reduced A1C similarly to metformin with greater weight gain, and there was comparable safety over 24 weeks in the treatment of pediatric subjects with type 2 diabetes.